Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1993 Feb;67(2):388–390. doi: 10.1038/bjc.1993.71

Oral piritrexim, an effective treatment for metastatic urothelial cancer.

R de Wit 1, S B Kaye 1, J T Roberts 1, G Stoter 1, J Scott 1, J Verweij 1
PMCID: PMC1968166  PMID: 8431372

Abstract

Piritrexim is a lipid-soluble inhibitor of dihydrofolate reductase (DHFR) that enters tumour cells rapidly by passive diffusion, cannot be polyglutamated, and is as effective as methotrexate in inhibiting DHFR. Bioavailability after oral dosing is approximately 75%. We performed a phase II study with oral piritrexim in non-chemotherapy pretreated patients with metastatic urothelial cancer. Thirty-three patients were treated with 25 mg three times daily for 5 consecutive days, repeated weekly, with provision for dose escalation or reduction according to the toxicity observed. Of 29 evaluable patients, one patient achieved a complete response of 19+ weeks duration, and ten patients achieved a partial response with a median duration of 22 weeks (range 16-48), for a total response rate of 38%. Piritrexim was generally well tolerated, with myelosuppression as the major toxicity, that frequently required dose modification. We conclude that piritrexim appears to be an active agent in patients with metastatic urothelial cancer when administered as a 5-day, low-dose oral schedule. It would be attractive to investigate the combination of piritrexim and cisplatin.

Full text

PDF
388

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Duch D. S., Edelstein M. P., Bowers S. W., Nichol C. A. Biochemical and chemotherapeutic studies on 2,4-diamino-6-(2,5-dimethoxybenzyl)-5-methylpyrido[2,3-d]pyrimidine (BW 301U), a novel lipid-soluble inhibitor of dihydrofolate reductase. Cancer Res. 1982 Oct;42(10):3987–3994. [PubMed] [Google Scholar]
  2. Feun L. G., Gonzalez R., Savaraj N., Hanlon J., Collier M., Robinson W. A., Clendeninn N. J. Phase II trial of piritrexim in metastatic melanoma using intermittent, low-dose administration. J Clin Oncol. 1991 Mar;9(3):464–467. doi: 10.1200/JCO.1991.9.3.464. [DOI] [PubMed] [Google Scholar]
  3. Feun L. G., Savaraj N., Benedetto P., Hanlon J., Sridhar K. S., Collier M., Richman S., Liao S. H., Clendeninn N. J. Phase I trial of piritrexim capsules using prolonged, low-dose oral administration for the treatment of advanced malignancies. J Natl Cancer Inst. 1991 Jan 2;83(1):51–55. doi: 10.1093/jnci/83.1.51. [DOI] [PubMed] [Google Scholar]
  4. Harker W. G., Meyers F. J., Freiha F. S., Palmer J. M., Shortliffe L. D., Hannigan J. F., McWhirter K. M., Torti F. M. Cisplatin, methotrexate, and vinblastine (CMV): an effective chemotherapy regimen for metastatic transitional cell carcinoma of the urinary tract. A Northern California Oncology Group study. J Clin Oncol. 1985 Nov;3(11):1463–1470. doi: 10.1200/JCO.1985.3.11.1463. [DOI] [PubMed] [Google Scholar]
  5. Hillcoat B. L., Raghavan D., Matthews J., Kefford R., Yuen K., Woods R., Olver I., Bishop J., Pearson B., Coorey G. A randomized trial of cisplatin versus cisplatin plus methotrexate in advanced cancer of the urothelial tract. J Clin Oncol. 1989 Jun;7(6):706–709. doi: 10.1200/JCO.1989.7.6.706. [DOI] [PubMed] [Google Scholar]
  6. Khandekar J. D., Elson P. J., DeWys W. D., Slayton R. E., Harris D. T. Comparative activity and toxicity of cis-diamminedichloroplatinum (DDP) and a combination of doxorubicin, cyclophosphamide, and DDP in disseminated transitional cell carcinomas of the urinary tract. J Clin Oncol. 1985 Apr;3(4):539–545. doi: 10.1200/JCO.1985.3.4.539. [DOI] [PubMed] [Google Scholar]
  7. Logothetis C. J., Dexeus F. H., Finn L., Sella A., Amato R. J., Ayala A. G., Kilbourn R. G. A prospective randomized trial comparing MVAC and CISCA chemotherapy for patients with metastatic urothelial tumors. J Clin Oncol. 1990 Jun;8(6):1050–1055. doi: 10.1200/JCO.1990.8.6.1050. [DOI] [PubMed] [Google Scholar]
  8. Logothetis C. J., Dexeus F. H., Sella A., Amato R. J., Kilbourn R. G., Finn L., Gutterman J. U. Escalated therapy for refractory urothelial tumors: methotrexate-vinblastine-doxorubicin-cisplatin plus unglycosylated recombinant human granulocyte-macrophage colony-stimulating factor. J Natl Cancer Inst. 1990 Apr 18;82(8):667–672. doi: 10.1093/jnci/82.8.667. [DOI] [PubMed] [Google Scholar]
  9. Oliver R. T., Kwok H. K., Highman W. J., Waxman J. Methotrexate, cisplatin and carboplatin as single agents and in combination for metastatic bladder cancer. Br J Urol. 1986 Feb;58(1):31–35. doi: 10.1111/j.1464-410x.1986.tb05423.x. [DOI] [PubMed] [Google Scholar]
  10. Sedwick W. D., Hamrell M., Brown O. E., Laszlo J. Metabolic inhibition by a new antifolate, 2,4-diamino-6-(2,5-dimethoxybenzyl)-5-methyl-pyrido[2,3-d]pyrimidine (BW3O1U), an effective inhibitor of human lymphoid and dihydrofolate reductase-overproducing mouse cell lines. Mol Pharmacol. 1982 Nov;22(3):766–770. [PubMed] [Google Scholar]
  11. Sigel C. W., Macklin A. W., Woolley J. L., Jr, Johnson N. W., Collier M. A., Blum M. R., Clendeninn N. J., Everitt B. J., Grebe G., Mackars A. Preclinical biochemical pharmacology and toxicology of piritrexim, a lipophilic inhibitor of dihydrofolate reductase. NCI Monogr. 1987;(5):111–120. [PubMed] [Google Scholar]
  12. Sternberg C. N., Yagoda A., Scher H. I., Watson R. C., Geller N., Herr H. W., Morse M. J., Sogani P. C., Vaughan E. D., Bander N. Methotrexate, vinblastine, doxorubicin, and cisplatin for advanced transitional cell carcinoma of the urothelium. Efficacy and patterns of response and relapse. Cancer. 1989 Dec 15;64(12):2448–2458. doi: 10.1002/1097-0142(19891215)64:12<2448::aid-cncr2820641209>3.0.co;2-7. [DOI] [PubMed] [Google Scholar]
  13. Stoter G., Splinter T. A., Child J. A., Fosså S. D., Denis L., van Oosterom A. T., de Pauw M., Sylvester R. Combination chemotherapy with cisplatin and methotrexate in advanced transitional cell cancer of the bladder. J Urol. 1987 Apr;137(4):663–667. doi: 10.1016/s0022-5347(17)44168-1. [DOI] [PubMed] [Google Scholar]
  14. Troner M., Birch R., Omura G. A., Williams S. Phase III comparison of cisplatin alone versus cisplatin, doxorubicin and cyclophosphamide in the treatment of bladder (urothelial) cancer: a Southeastern Cancer Study Group trial. J Urol. 1987 Apr;137(4):660–662. doi: 10.1016/s0022-5347(17)44167-x. [DOI] [PubMed] [Google Scholar]
  15. Weiss G. R., Sarosy G. A., Shenkenberg T. D., Williams T., Clendeninn N. J., Von Hoff D. D., Woolley J. L., Liao S. H., Blum M. R. A phase I clinical and pharmacological study of weekly intravenous infusions of piritrexim (BW301U). Eur J Cancer Clin Oncol. 1989 Dec;25(12):1867–1873. doi: 10.1016/0277-5379(89)90360-x. [DOI] [PubMed] [Google Scholar]
  16. Yagoda A. Chemotherapy of urothelial tract tumors. Cancer. 1987 Aug 1;60(3 Suppl):574–585. doi: 10.1002/1097-0142(19870801)60:3+<574::aid-cncr2820601524>3.0.co;2-c. [DOI] [PubMed] [Google Scholar]
  17. Yagoda A. The role of cisplatin-based chemotherapy in advanced urothelial tract cancer. Semin Oncol. 1989 Aug;16(4 Suppl 6):98–104. [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES